Friday, October 09, 2009
BioGeneration Ventures (BGV), a fund that is dedicated
to assisting start-ups and early stage companies seeking to commercialise cutting-edge research in life sciences,
has made a significant investment in the biopharmaceutical company arGEN-X.
arGEN-X is a research stage biopharmaceutical company with
a broadly applicable, proprietary SIMPLE Antibody™ platform.
The platform allows arGEN-X to create an unparalleled diversity
of in vivo generated antibody leads against a broad range of human disease targets.
Read more